StockNews.com Downgrades Immunic (NASDAQ:IMUX) to Sell

Immunic (NASDAQ:IMUX) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Thursday.

Other research analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Immunic in a report on Friday, February 21st. D. Boral Capital reiterated a “buy” rating and set a $17.00 price target on shares of Immunic in a report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $12.67.

Immunic Stock Performance

Shares of IMUX stock opened at $1.16 on Thursday. Immunic has a fifty-two week low of $0.92 and a fifty-two week high of $2.11. The stock’s fifty day moving average is $1.06 and its two-hundred day moving average is $1.22. The firm has a market capitalization of $104.49 million, a P/E ratio of -0.94 and a beta of 1.89.

Institutional Trading of Immunic

A number of hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp increased its position in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares during the last quarter. 683 Capital Management LLC increased its position in shares of Immunic by 2.2% during the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after purchasing an additional 15,349 shares during the last quarter. Bridgeway Capital Management LLC grew its position in Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock valued at $215,000 after acquiring an additional 22,200 shares in the last quarter. Focus Partners Wealth grew its position in Immunic by 1.1% in the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after acquiring an additional 23,610 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Immunic in the 3rd quarter valued at about $50,000. 51.82% of the stock is owned by institutional investors and hedge funds.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.